Ménégaut, Louise
Laubriet, Aline
Crespy, Valentin
Leleu, Damien
Pilot, Thomas
Van Dongen, Kevin
de Barros, Jean-Paul Pais
Gautier, Thomas
Petit, Jean-Michel
Thomas, Charles
Nguyen, Maxime
Steinmetz, Eric
Masson, David
Funding for this research was provided by:
Conseil régional de Bourgogne-Franche-Comté
CHU Dijon Bourgogne
Agence Nationale de la Recherche (ANR-11-LABX-0021)
Article History
Received: 17 July 2023
Accepted: 3 September 2023
First Online: 14 September 2023
Declarations
:
: The MASCADI protocol was reviewed and approved by the regional Ethics Committee (Comité de Protection des Personnes Est, Dijon, France CPP Est III, CHRU Nancy, N° 2017-A00022-51) and recorded on ClinicalTrials.gov (clinical registration number: NCT03202823). According to the trial category (Interventional research that does not involve drugs or non-CE-marked medical devices and that involves only minimal risks and constraints for the patient) and the ethics committee, all patients received written information note on the study. Oral consent was obtained from the patient and an attestation of the patient’s oral consent was signed by the investigator physician and countersigned by the patient, according to the french law in this type of trial.
: N.A.
: The authors have no conflict of interest to disclose.